Pulmozyme Efficacy & Tolerability: Lung Function
Help patients improve lung function with Pulmozyme
Pulmozyme provided sustained lung function improvement in patients with FVC>40% predicted1
Young patients with early disease also benefitted from Pulmozyme in a 2-year clinical trial.
Pulmozyme maintained or improved lung function in patients with FVC ≥85% predicted, aged 6 to 10 years
FEF = forced expiratory flow between 25% and 75% of vital capacity
1. Pulmozyme SmPC, Electronic Medicines Compendium, accessed 10/8/18
25. Fuchs HJ et al. Effect of aerosolized recombinant humsn Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.
26. Quan JM et al. A two-year randomized. Placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139(6):813-820.
Learn more about cystic fibrosis at managingcysticfibrosis.com
This website contains information which can target a wide range of audiences and could contain details and information not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
M-XX-00000028 | Date of preparation: October 2019
